Citigroup Inc Impel Pharmaceuticals Inc Transaction History

Citigroup Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 09, 2023	SELL	$2.59 - $4.0 $727 - $1,124	-281 Reduced 81.45%	64 $0
Q3 2022 Nov 10, 2022	SELL	$5.78 - $9.32 $346 - $559	-60 Reduced 14.81%	345 $2,000
Q2 2022 Aug 10, 2022	SELL	$5.83 - $10.12 $1,929 - $3,349	-331 Reduced 44.97%	405 $4,000
Q1 2022 May 12, 2022	SELL	$5.86 - $9.85 $7,741 - $13,011	-1,321 Reduced 64.22%	736 $5,000
Q4 2021 Feb 10, 2022	BUY	$8.33 - $12.14 $11,936 - $17,396	1,433 Added 229.65%	2,057 $18,000
Q3 2021 Nov 10, 2021	BUY	$8.38 - $26.13 $5,229 - $16,305	624 New	624 $8,000

14.4K

Ticker IMPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 23,738,800
Market Cap $475K
Description
Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The c...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.